Results 241 to 250 of about 436,330 (367)

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

A Systematic Review of the Use of Janus Kinase Inhibitors in Large Vessel Vasculitis. [PDF]

Cureus
Chay T, Patel T, Dumaru N, Maddukuri S, Haddad RR, Battula NS, Mohammed L.   +6 more
europepmc   +1 more source

miR‑20a‑5p inhibits endometrial cancer progression by targeting janus kinase 1

, 2021
Ying He, Hui Ma, Jing Wang, Yanhua Kang, Qianlong Xue   +4 more
openalex   +2 more sources

Histopathological Characterization and Differential Expression of miRNAs in Male Pediatric Patients With Lichen Sclerosus

Andrology, EarlyView.
ABSTRACT Background Lichen sclerosus is a chronic, inflammatory, scarring disease of the skin that manifests mostly in the genital region. Objective We studied the histomorphological characteristics, grade, and pattern of inflammation in male pediatric patients with lichen sclerosus.
Valerie Flammang, Arndt Hartmann, Robert Stöhr, Katrin Weigelt, Carol Geppert, Frederik A. Stuebs, Matthias W. Beckmann, Bernd Wullich, Helge Taubert, Marios Marcou, Sven Wach   +10 more
wiley   +1 more source

Janus kinase inhibitors - a role for the treatment of cutaneous T-cell lymphomas? [PDF]

Oncol Rev
Packer SE, Brunner PM.
europepmc   +1 more source

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

British Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan, Imran Omerdeen, Bethan Psaila   +2 more
wiley   +1 more source

Revisiting Janus Kinase Inhibitors in Hospitalized COVID-19: Evidence for Baricitinib's Superiority and the Absence of a Class Effect. [PDF]

J Inflamm Res
Gu L, Lin J, Yue J, Liu Z, Huang JA.
europepmc   +1 more source

Supplementary Table 1, Figures 1 - 2 from The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers <i>In Vitro</i> and <i>In Vivo</i>

, 2023
Jih‐Hsiang Lee, Kang‐Seo Park, Anna Teresa Alberobello, Bhaskar Kallakury, Meng‐Tzu Weng, Yisong Wang, Giuseppe Giaccone   +6 more
openalex   +2 more sources

Adverse effects of Janus kinase inhibitors with relevance for daily practice in dermatology. [PDF]

J Dtsch Dermatol Ges
Rajput Khokhar A, Ghoreschi K, Huynh J.
europepmc   +1 more source

Comparative short-term efficacy of Janus kinase 1 inhibitors and anti-interleukin-13 antibodies in atopic dermatitis: a retrospective cohort analysis based on real-world data [PDF]

Emi Sato, Naoko Obonai, Mayuko Iwata, Kotaro Ito, Shinichi Imafuku   +4 more
openalex   +1 more source